CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11202-11208

  Zhang, Zhengyan ^a   Borecki, Ingrid ^a   Nguyen, Loan ^a   Ma, Duanduan ^a   Smith, Kimberly ^a   Huettner, Phyllis C ^a   Mutch, David G ^a   Herzog, Thomas J ^a   Gibb, Randall K ^a   Powell, Matthew A ^a   Grigsby, Perry W ^a   Massad, L Stewart ^b   Hernandez, Enrique ^c   Judson, Patricia L ^d   Swisher, Elizabeth M ^e   Crowder, Sara ^f   Li, Jianduan ^a   Gerhard, Daniela S ^a,g   Rader, Janet S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f Mid Missouri Gynecologic Oncology   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN;

ALLELE; ARTICLE; CANCER INVASION; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GOLGI COMPLEX; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; INTRON; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ANTIGENS, CD; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CHROMOSOMES, HUMAN, PAIR 6; EXONS; EXPRESSED SEQUENCE TAGS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOGLOBULINS; LOSS OF HETEROZYGOSITY; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 37049011866     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2677     Document Type: Article

References (42)

1. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.
2. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
3. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2:59-65.
4. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30.
5. Wang SS, Hildesheim A. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003;31:35-40.
6. Neuman RJ, Huettner PC, Li L, et al. Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstet Gynecol 2000;95:134-40.
7. Orth G. Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol 2002;18:362-74.
8. Fitzpatrick MA, Funk MC, Gius D, et al. Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive carcinoma using alignment of DNA microarray data. Gynecol Oncol 2006;103:458-62.
9. Zhang Z, Gerhard DS, Nguyen L, et al. Fine mapping and evaluation of candidate genes for cervical cancer on 11q23. Genes Chromosomes Cancer 2005;43:95-103.
10. Umayahara K, Numa F, Suehiro Y, et al. Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosomes Cancer 2002;33:98-102.
11. Rader JS, Gerhard DS, O'Sullivan MJ, et al. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer 1998;22:57-65.
12. Rader JS, Kamarasova T, Huettner PC, et al. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene 1996;13:2737-41.
13. Rader JS, Li Y, Huettner PC, Xu Z, Gerhard DS. Cervical cancer suppressor gene is within 1 cM on 6p23. Genes Chromosomes Cancer 2000;27:373-9.
14. de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23.
15. Chang YE, Pena L, Sen GC, Park JK, Laimins LA. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J Virol 2002;76:8864-74.
16. Zhang Z, Huettner PC, Nguyen L, et al. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 2006;25:5436-45.
17. Klein E, Koch S, Borm B, et al. CD83 localization in a recycling compartment of immature human monocyte-derived dendritic cells. Int Immunol 2005;17:477-87.
18. Li J, Gerhard DS, Zhang Z, et al. Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. J Clin Microbiol 2003;41:5563-71.
19. Clayton D, Jones H. Transmission/disequilibrium tests for extended marker haplotypes. Am J Hum Genet 1999;65:1161-9.
20. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Optimal designs for two-stage genome-wide association studies. Genet Epidemiol 2007;31:776-88.
21. Wright JD, Li J, Gerhard DS, et al. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol 2005;98:84-91.
22. Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996;88:1361-8.
23. Okazaki Y, Furuno M, Kasukawa T, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002;420:563-73.
24. Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420:520-62.
25. Hasina R, Pontier AL, Fekete MJ, et al. NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype. Oncogene 2006;25:588-98.
26. Gius D, Funk MC, Chuang EY, et al. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res 2007;67:7113-23.
27. Zhao H. Family-based association studies. Stat Methods Med Res 2000;9:563-87.
28. Lechmann M, Zinser E, Golka A, Steinkasserer A. Role of CD83 in the immunomodulation of dendritic cells. Int Arch Allergy Immunol 2002;129:113-8.
29. Breloer M, Kretschmer B, Luthje K, et al. CD83 is a regulator of murine B cell function in vivo. Eur J Immunol 2007;37:634-48.
30. + T cells. J Immunol 2004;173:2995-3001.
31. Scholler N, Hayden-Ledbetter M, Dahlin A, et al. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol 2002;168:2599-602.
32. Luthje K, Cramer SO, Ehrlich S, et al. Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells. Eur J Immunol 2006;36:2035-45.
33. + T cell development in the thymus. Cell 2002;108:755-67.
34. Lechmann M, Krooshoop DJ, Dudziak D, et al. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med 2001;194:1813-21.
35. Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 2004;103:4207-15.
36. Berchtold S, Muhl-Zurbes P, Maczek E, et al. Cloning and characterization of the promoter region of the human CD83 gene. Immunobiology 2002;205:231-46.
37. Dudziak D, Kieser A, Dirmeier U, et al. Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-κB signaling pathway. J Virol 2003;77:8290-8.
38. Prechtel AT, Chemnitz J, Schirmer S, et al. Expression of CD83 is regulated by HuR via a novel cis-active coding region RNA element. J Biol Chem 2006;281:10912-25.
39. Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol 2005;174:6672-6.
40. Andersen JM, Al-Khairy D, Ingalls RR. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 2006;74:824-31.
41. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8:209-20.
42. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.